The first trading week of 2022 went with a bang in financial markets, and sent a clear message that this year will not be for the faint-hearted.
In fairness, investors and analysts knew it was likely to be lively. The US Federal Reserve — the markets’ firefighter-in-chief — had made clear that it was winding down its Covid-era stimulus in the face of bubbling inflation. At its policy-setting meeting in December, it had already bumped up the pace at which it will reduce asset purchases in what has become known as its “hawkish pivot”.
Casting ahead into this year, it does not take a markets savant to figure out that the full withdrawal of support and the introduction of US interest-rate rises (remember them?) will present a challenging environment for risky assets pumped higher by the Fed’s economic largesse. In layman’s terms: what goes up must come down. So, fund managers were prepared for volatility. Even if we end up higher in major stocks indices by the time the year is out, setbacks are inevitable.
Nonetheless, the release this week of the minutes of the last Fed meeting left a mark.
“The minutes are usually uneventful, but certain statements suggest that the Fed is willing to hike rates sooner and faster than what investors were assuming,” said Solita Marcelli, chief investment officer for the Americas at UBS Global Wealth Management, acknowledging that she, along with plenty of other investors, had been caught somewhat off guard.
In combination with signs that the Fed is looking at the details of how to cut back its $9tn balance sheet, Wednesday’s minutes prompted traders to amp up bets on a rate rise as soon as March.
“Much to the surprise of the market, [rate setters] seem to agree that the balance sheet needs to be reduced even faster than in 2018, an episode often seen as a policy mistake,” said Markus Allenspach, head of fixed income research at Julius Baer.
First against the wall, predictably enough, were highly speculative tech stocks. Or, as Hani Redha, a portfolio manager at PineBridge Investments, put it: “Spec-tech is getting wrecked.” An early contender for markets quote of the year, there.
The tech-heavy Nasdaq Composite index closed more than 3 per cent lower on Wednesday in its worst performance in almost a year. Cathie Wood’s flagship exchange traded fund, famed for its bets on often unproven technology companies that do not yet turn a profit, continued its miserable run, leaving it down almost 10 per cent just this year. Crypto, the planet’s most speculative bet, also suffered, with bitcoin down nearly 10 per cent at $41,450 a pop. Aside from a weekend flash crash in early December, that is the lowest since October.
Government bond prices have also taken a knock. Yields on benchmark 10-year US government bonds ended 2021 at just 1.5 per cent, well below most predictions. But they have swept up to about 1.75 per cent. This inevitably dulls the comparative allure of long-term speculative investments.
It all sets the scene for a tense tug of war between the Fed and fund managers this year. Mark Dowding, chief investment officer at BlueBay Asset Management, notes that in this process, the Fed’s messaging is tightly choreographed.
“Last year, the Fed wanted to move quite cautiously away from being ultra-accommodative to more neutral. They didn’t want to upset markets, and wanted to tread ever so carefully,” he said. “But lately it has been taking baby steps to see if the market will throw its toys out of the pram.”
After the last Fed decision, one of the central bank’s governors, Christopher Waller, firmly planted the notion that rate rises start in March to tackle “alarmingly high inflation”. Toy check: still in the pram.
Then at the very start of 2022, right before the minutes were released and with stocks indices still close to record highs, The Wall Street Journal gave some tasters on policymakers’ thinking, reporting that officials are “beginning to map out how and when” to shrink the central bank’s balance sheet. Again, toys remained in place.
“It turns out that markets are comfortable with three hikes this year, and three the following year, which still only takes us to 1.5 per cent by the end of 2023,” said Dowding.
Some of the froth has been blown aside, for sure. But a drop in the US’s benchmark S&P 500 stocks index of around 2 per cent on the week is hardly enough to spark soul-searching at the Fed over some terrible error. Crucially, too, the declines we have seen are from extremely elevated levels.
The Fed is still likely to consider pulling back if fund managers really start bawling. As Marcelli at UBS has suggested, the game remains the same: stick to cyclical bets. “Growth companies had been the main beneficiaries of extraordinarily low real and nominal interest rates,” she wrote. “As the Fed begins to normalise policy, it’s logical that these stocks will face the strongest headwinds. Within the US equity market we continue to have a preference for value stocks over growth stocks.”
Growth stocks fanatics who have not figured this out yet will have to learn to cry it out.
levofloxacin oral order levofloxacin 500mg generic
avodart online buy celecoxib pills zofran canada
buy spironolactone 25mg for sale valtrex 1000mg pill fluconazole usa
order ampicillin 500mg sale cheap cephalexin 125mg order erythromycin 500mg without prescription
sildenafil usa buy robaxin pill order methocarbamol sale
buy suhagra 100mg online cheap aurogra 100mg over the counter estrace 1mg ca
isotretinoin 10mg cost order zithromax 500mg generic azithromycin
tadalafil 5mg gГ©nГ©rique generique tadalafil 20mg acheter 100mg viagra en ligne
altace 5mg us irbesartan over the counter azelastine 10 ml cost
alendronate 70mg tablet order motrin generic famotidine for sale online
benicar 10mg canada calan generic diamox 250mg pill
buy dapsone 100 mg avlosulfon 100 mg without prescription buy aceon pill
medroxyprogesterone 10mg drug buy periactin 4mg sale purchase periactin online cheap
provigil brand order modafinil 100mg generic stromectol 3 mg price
cialis order buy cialis 5mg pills buy sildenafil 50mg
metformin 1000mg drug order generic lipitor 10mg cialis 20mg tablet
purchase olanzapine pill buy nebivolol 20mg online cheap order generic diovan 80mg
brand lopressor 50mg metoprolol for sale online levitra for sale online
buying a research paper for college online casino for real cash play money poker online
how to write a letter to a hiring manager paper help viagra 100mg cheap
tadalafil 40mg cheap order sildenafil 100mg online sildenafil pharmacy
aristocort 10mg canada claritin cheap desloratadine 5mg for sale
order cialis 10mg pills sildenafil 50mg cost viagra pills 150mg
orlistat uk order generic acyclovir 800mg cheap acyclovir
order lioresal without prescription generic tizanidine cheap toradol 10mg
sumatriptan online order oral levaquin 250mg dutasteride tablet
cost gloperba colchicine 0.5mg generic poker online best
best online poker sites for real money live dealer blackjack free roulette games
order viagra 50mg overnight delivery for viagra buy generic cialis
playing poker online for money online casino real money no deposit order tadalafil 20mg for sale
sildenafil 200mg price lamotrigine over the counter brand lamictal 50mg
order prednisone 20mg generic generic amoxicillin 1000mg buy amoxicillin 500mg generic
viagra 150mg for sale prices of cialis cialis next day delivery usa
blackjack online free cialis tablets tadalafil 10mg uk
buy azithromycin 500mg generic purchase prednisolone pill buy neurontin 800mg generic
play roulette slot game modafinil brand
order furosemide 100mg online order hydroxychloroquine 200mg online cheap hydroxychloroquine 400mg cheap
sildenafil 100mg uk purchase budesonide online order rhinocort for sale
prednisone 20mg cheap buy prazosin 1mg online mebendazole brand
purchase tretinoin generic tadalafil 10mg oral avana 100mg generic
order generic tadacip tadalafil generic buy indocin for sale